



PATENT  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. MBHB02-013)

In the Application of:

Sharma, et al.

Serial No. 10/043,774

Filing Date: January 10, 2002

For: Human Hematopoietic Growth  
Regulatory Gene and Uses

Before the Examiner:  
Terry A. McKelvey

Group Art Unit: 1636

**TRANSMITTAL LETTER**

Commissioner for Patents  
Alexandria, VA 22313-1450

Sir:

In regard to the above-identified application:

1. We are transmitting herewith the attached
  - a. Response to Office Action Mailed December 18, 2003
  - b. Declaration Pursuant to 37 C.F.R. § 1.132
  - c. Return Receipt Postcard
2. With respect to additional fees:
  - a. An additional fee of \$00.00 is required.
3. A check in the amount of \$00.00 is enclosed.
4. Please charge any deficiency in the amount due, or credit any overpayment, to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
5. **CERTIFICATE OF MAILING UNDER 37 CFR § 1.8:** The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 herein-above, are being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313, on this 18th day of March, 2004.

By

Kevin E. Noonan  
Reg. No. 35,303



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 02-013)

PATENT

In re Application of: Sharma et al.

Serial No.: 10/043,774

Filed: January 10, 2002

For: Human Hematopoietic Growth  
Regulatory Gene and Uses

Before the Examiner:  
Terry A. McKelvey Ph.D.

Group Art Unit: 1646

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**RESPONSE TO OFFICE ACTION MAILED DECEMBER 18, 2003**

Responsive to the Office Action mailed December 18, 2003, applicant respectfully requests reconsideration of the above-identified application in view of the following amendments and remarks.

**AMENDMENTS**

The Examiner is respectfully requested to enter the following amendments to the claims. Pursuant to revised 37 C.F.R. § 1.121, Applicants present the amendments to the claims at page 2. Remarks begin on page 5 of this response.